Compare Humana Inc (HUM) vs Spotify Technology (SPOT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Humana Inc vs Spotify Technology — how do they compare? Humana Inc trades at $442 (market cap $47.61B), while Spotify Technology trades at $528.44 (market cap $105.45B). The key difference: Spotify Technology is far larger — about 2.2× Humana Inc's market cap, and Humana Inc pays a 0.89% dividend while Spotify Technology pays none. Which is the better fit depends on your goals — on Pluang, investors hold Humana Inc for 53 Days and Spotify Technology for 111 Days on average.
| HUM | SPOT | |
|---|---|---|
Market Cap | $47.61B | $105.45B |
Volume | 1,827,332 | 2,000,851 |
Sector | Health | Media |
52-Week High | $409.85 | $692.04 |
52-Week Low | $163.67 | $412.75 |
Typical Hold Time | 53 Days | 111 Days |
Enterprise Value | $54.97B | $95.41B |
Dividend Yield | 0.89% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Humana (HUM) trades at $387.12, down 4.24% today, but maintains a bullish technical outlook with strong institutional support. The stock shows mixed fundamentals with revenue growth to $129.66B in 2025 but declining profit margins at 0.88%. Recent analyst upgrades, including Barclays' $515 target on September 25, 2026, highlight optimism despite ongoing Medicare Advantage plan adjustments affecting member transitions.
Investment outlook remains cautiously optimistic with a consensus price target of $432.63 offering 12% upside. Risks include margin compression, regulatory scrutiny from Medicare billing practices, and competitive pressures in managed care. The company's strong cash position of $20.44B and consistent dividend payments provide stability amid enrollment volatility.
Spotify (SPOT) trades at $526.42, up 7.84% with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with revenue growth from $15.7B to $17.2B in 2025 and net income surging to $2.2B. Recent Q2 2026 earnings missed expectations, but analyst consensus remains strongly bullish with a $610 price target. Technical indicators show support at $497 and resistance at $524, with the stock approaching key resistance levels.
Spotify presents a compelling growth story with expanding profit margins and strong cash flow generation. The primary investment opportunity lies in continued subscriber growth and margin expansion, though risks include competitive pressures in streaming and execution challenges. Wall Street maintains strong conviction with 62% buy ratings, suggesting 16% upside to consensus targets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Humana Inc
Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →About Spotify Technology
Spotify Technology S.A. provides music streaming services. The Company offers commercial-free music and ad-supported services to subscribers. Spotify Technology serves clients worldwide.
Read more on SPOT →
